Monthly Archives: January 2018

Gastroenterology is the premiere journal in the field of gastrointestinal disease and is led by an internationally renowned board of editors. As the official journal of the AGA Institute, Gastroenterology delivers up-to-date and authoritative coverag… Continue reading →

I read with interest the article by Park et al1 regarding the observation time of esophagogastroduodenoscopy (EGD) examination. In this retrospective study, the authors showed that slow endoscopists could detect neoplasms in 0.28% of patients as compa… Continue reading →

Question: A 12-year-old boy presented with a history of iron deficiency anemia for which he had taken oral iron supplementation for 2 years. He also complained of intermittent right hip pain in recent years. He had no weight loss, no prolonged fever… Continue reading →

We read with great interest the paper by van der Vlugt et al.1 The interval colorectal cancers (I-CRCs) detected in subjects after multiple rounds of a screening program based on the fecal immunochemical test (FIT) are one of our main interests. Our … Continue reading →

Clostridium difficile induces intestinal inflammation by releasing toxins A and B. The antimicrobial compound cationic steroid antimicrobial 13 (CSA13) has been developed for treating gastrointestinal infections. The CSA13-Eudragit formulation can be g… Continue reading →

Pancreatic acinar cells are polarized epithelial cells that store enzymes required for digestion as inactive zymogens, tightly packed at the cell apex. Stimulation of acinar cells causes the zymogen granules to fuse with the apical membrane, and the ce… Continue reading →

The rare emergence of hepatitis B virus (HBV) reactivation among hepatitis C virus (HCV)-infected patients receiving direct-acting antiviral (DAA) therapy raises questions about how many HCV-infected patients have active, past, or latent/occult HBV co-… Continue reading →

Approximately 1/3rd of the patients with ulcerative colitis (UC) and 70% of those with Crohn’s disease (CD) undergo surgery over their lifetime. Nutritional optimization is a cornerstone of successful surgical outcomes in inflammatory bowel disease (… Continue reading →

While phase II-III trials clearly demonstrated efficacy of tofacitinib, an oral small molecule pan-JAK inhibitor, in patients with UC, in CD tofacitinib did not differ from placebo, raising questions about the design of those trials but also about tofa… Continue reading →

Tumor necrosis factor inhibitors (TNFi) are effective treatments for ulcerative colitis (UC). The TNFi certolizumab pegol (CZP) is effective in Crohn’s disease, and an open label (OL) study suggested that CZP is effective for induction of response in… Continue reading →